For the third quarter of the fiscal year ending March 2026, revenue was 154,864 million yen (8.1% Year-over-Year increase), operating income was 15,943 million yen (25.7% Year-over-Year decrease), and net income attributable to owners of parent for the quarter was 10,749 million yen (57.8% Year-over-Year decrease).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4887","jir_company_name":"Sawai Group Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4887-20260213-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, revenue was 154,864 million yen (8.1% Year-over-Year increase), operating income was 15,943 million yen (25.7% Year-over-Year decrease), and net income attributable to owners of parent for the quarter was 10,749 million yen (57.8% Year-over-Year decrease).","jir_summary":"### Performance Overview\nConsolidated results for the third quarter of the fiscal year ending March 2026 showed revenue of 154,864 million yen (8.1% Year-over-Year increase), while operating income declined to 15,943 million yen (25.7% Year-over-Year decrease) and net income attributable to owners of parent for the quarter decreased to 10,749 million yen (57.8% Year-over-Year decrease). Core operating income reached 23,118 million yen (1.1% Year-over-Year increase), indicating steady profit excluding non-recurring factors. The U.S. business is classified as discontinued operations, and revenue and other figures are presented for continuing operations only.\n\n### Financial Position and Cash Flows\nTotal assets stood at 377,030 million yen, an increase of 22,408 million yen compared to the end of the previous consolidated fiscal year. Total liabilities increased by 17,461 million yen to 198,230 million yen, and total equity increased by 4,946 million yen to 178,800 million yen. Cash and cash equivalents were 46,122 million yen, up 7,336 million yen from the end of the previous year. Cash flow from operating activities was an inflow of 2,846 million yen, investing activities resulted in an outflow of 19,150 million yen, and financing activities provided an inflow of 23,571 million yen.\n\n### Business Environment and Future Initiatives\nIn light of the expanding generic pharmaceutical market and government policies aimed at supply stabilization, the company is advancing its medium-term management plan 'Beyond 2027.' It pursues a multifaceted growth strategy including strengthening quality control, enhancing production capacity, and expanding its digital healthcare business. Earnings per share, adjusted for the stock split in October 2024 (1 share \u2192 3 shares), was 93.09 yen. Full-year earnings guidance forecasts revenue of 202,500 million yen, operating income of 20,900 million yen, and net income attributable to owners of parent of 14,000 million yen.","jir_financial_highlights":"Revenue: 154,864 million yen (8.1% Year-over-Year increase)\nOperating Income: 15,943 million yen (25.7% Year-over-Year decrease)\nNet Income Attributable to Owners of Parent for the Quarter: 10,749 million yen (57.8% Year-over-Year decrease)\nCore Operating Income: 23,118 million yen (1.1% Year-over-Year increase)\nNumber of Shares Outstanding (at period end): 115,487,137 shares (Unknown)\nNumber of Treasury Shares (at period end): 1,503 shares (Unknown)","jir_category":"","jir_hashtags":"#SawaiGroupHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: 154,864 million yen (8.1% Year-over-Year increase)\nOperating Income: 15,943 million yen (25.7% Year-over-Year decrease)\nNet Income Attributable to Owners of Parent for the Quarter: 10,749 million yen (57.8% Year-over-Year decrease)","jir_meta_title":"Sawai Group Holdings Q3 FY2026 Financial Summary: Revenue of 154,864 million yen (8.1% YoY Growth)","jir_meta_description":"Sawai Group Holdings Co., Ltd. releases its Q3 FY2026 financial summary. Revenue reached 154,864 million yen (8.1% YoY increase), operating income was 15,943 million yen (25.7% decline), and net income attributable to owners of parent was 10,749 million yen (57.8% decline).","jir_og_title":"Sawai Group Holdings FY2026 Q3 Financial Highlights","jir_og_description":"Third quarter financial summary for FY ending March 2026. Revenue rose 8.1% YoY to 154,864 million yen, while operating income declined 25.7% to 15,943 million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[143208,154864],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[21472,15943],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income Attributable to Owners of Parent\\\",\\\"data\\\":[25456,10749],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income\\\",\\\"data\\\":[22857,23118],\\\"borderColor\\\":\\\"#76b7b2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Breakdown by Therapeutic Category (Q3 FY2026)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Cardiovascular Drugs\\\",\\\"Central Nervous System Drugs\\\",\\\"Other Metabolic Pharmaceuticals\\\",\\\"Gastrointestinal Drugs\\\",\\\"Blood and Body Fluid Drugs\\\",\\\"Antibiotic Preparations\\\",\\\"Allergy Drugs\\\",\\\"Respiratory Drugs\\\",\\\"Vitamins\\\",\\\"Oncology Drugs\\\",\\\"Chemotherapy Agents\\\",\\\"Urogenital and Anorectal Drugs\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[35233,21733,18994,17157,15471,7500,5910,5874,5563,5264,4970,4159,7038],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\",\\\"#59a14f\\\",\\\"#edc949\\\",\\\"#af7aa1\\\",\\\"#ff9da7\\\",\\\"#9c755f\\\",\\\"#bab0ac\\\",\\\"#86bcB6\\\",\\\"#d37295\\\",\\\"#fabfd2\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}]","ir_related_company":8760,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-28910","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n